Calendario›KARD›danicamtiv · KINSHIP-DCM
danicamtiv · KINSHIP-DCM
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Ensayo de Kardigan, Inc. en Miocardiopatia dilatada genetica sintomatica.
- Fase
- Fase 2/3
- Estado
- Reclutando pacientes
- Participantes
- 332
- Centros
- 78
- Fin del objetivo primario
- sep 2027
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en feb 2026.
Qué mide
Parte 1: Cambio desde el inicio (dia 1) hasta la semana 26 en el indice de funcion auricular izquierda en la cohorte 1 (26 semanas)
Qué se prueba
El estudio evalua como funciona danicamtiv comparado con placebo, y su seguridad, en personas con miocardiopatia dilatada genetica y familiar.
Lo que dice el documentoThe purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons.
Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM. The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM). The main goals of the study are: * To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv Participants will: * Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up
Más ensayos de KARD
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Tonlamarsen · KARDINAL-ASH | Fase 2 | Reclutando pacientes | dic 2026 (prevista) |
| Ataciguat · KATALYST-AV | Fase 2/3 | Reclutando pacientes | ago 2028 (prevista) |
| Danicamtiv · KINSHIP-OLE | Fase 3 | Reclutando pacientes | nov 2032 (prevista) |
| Tonlamarsen | Fase 2 | Completado | ene 2026 (real) |
Todos los de KARD, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07210723), actualizada en jul 2026.